

First International Meeting on ERK5 Signaling



July 14th and 15th 2022

BARCELONA



FIRST INTERNATIONAL MEETING ON ERK5 SIGNALING

BARCELONA, July 14th and 15th 2022



CONGRESS ORGANIZERS:

Dr. Jose M Lizcano. VHIR Research Institute and Universitat Autònoma de Barcelona. Spain

Dr. Elisabetta Rovida. University of Florence. Italy

Dr. Miguel F Segura. VHIR Research Institute, Barcelona. Spain

ERK5meetingbcn@gmail.com

VENUE:

VHIO Conference room

Vall d'Hebron Barcelona Hospital Campus

Centro Cellex,

Carrer de Natzaret, 115-117, 08035 Barcelona

<https://goo.gl/maps/cXMq1mfdAHhbcc9J8>

REGISTRATION:

Registration fee: 100,00€

Lunches and coffee breaks included.

Registrations must be made through the website:

aula.vallhebron.com (future courses section)

TECHNICAL SECRETARY:

Aula Vall d'Hebron -

inscripcionesaulavh@vhebron.net - +34 693785436

FIRST INTERNATIONAL MEETING ON ERK5 SIGNALING

BARCELONA, July 14th and 15th 2022

Thursday July 14th

09:00 - 09:30	Welcome. Elisabetta Rovida, Miguel Segura and Jose M Lizcano
09:30 - 10:20	Session 1 - Moderator: Atanasio Pandiella
09:30 - 09:55	Cathy Tournier (Manchester University, UK) ERK5 and cancer: What have we learned from transgenic mouse models?
09:55 - 10:20	Ricardo Sánchez Prieto (IIB, Madrid, Spain) ERK5 mediates chemical sarcomagenesis via KLF2
10:20 - 11:20	Coffe break
11:20 - 12:55	Session 2 - Moderator: Simon Cook
11:20 - 11:45	Katherine G Finegan (Manchester University, UK) Development of novel inhibitors that target the catalytic and non-catalytic functions of ERK5.
11:45 - 12:10	Emanuele Giurisato (University of Siena, Italy) Role of Myeloid ERK5 in cancer
12:10 - 12:30	Ignazia Tusa, (University of Florence, Italy) Identification of a cross-talk between MEK5-ERK5 and Hedgehog-GLI pathways in melanoma
12:30 - 12:55	Jose M Lizcano (VHIR, Barcelona, Spain) ERK5-NF-κB pathway: a new target in endometrial cancer
13:00 - 14:15	Lunch
14:15 - 15:45	Session 3 - Moderator Jose Lizcano
14:15 - 14:40	Simon Cook (Babraham Institute, Cambridge, UK) Paradoxical activation of ERK5 by ERK5 kinase inhibitors – challenge or opportunity?
14:40 - 15:00	Sergio Espinosa (VHIR, Barcelona, Spain) ERK5 opens the DOR to death receptor ligand-based anticancer therapy
15:00 - 15:20	Sofia Matilla-Almazán (IBSAL, Salamanca, Spain) Biomarking the MEK5/ERK5 pathway
15:20 - 15:45	Elisabetta Rovida (University of Florence, Italy) Targeting ERK5 in human melanoma
15.45 - 16.45	Coffe break
16:45 - 18.:00	Session 4 - Moderator: Martin Villalba
16:45 - 17:10	Jun-ichi Abe The University of Texas MD Anderson Cancer Center, TX USA ERK5 S496 phosphorylation, but not ERK5 kinase or transcriptional activity, is responsible for promoting macrophage inflammation and mitochondrial dysfunction via upregulating novel site of NRF2 K518 SUMOylation
17:10 - 17:35	Greg Findlay (University of Dundee, U.K.) ERK5 Functions in Pluripotent Stem Cells
17:35 - 18:00	Mike J Cross (University of Liverpool, U.K.) Statin mediated ERK5 activity and vascular protection against doxorubicin-induced cardiotoxicity

FIRST INTERNATIONAL MEETING ON ERK5 SIGNALING

BARCELONA, July 14th and 15th 2022

Friday July 15th

9:00 - 10:15	Session 5 - Moderator: Cathy Tournier
9:00 - 9:25	Miguel F Segura (VHIR, Barcelona, Spain) Nuclear and cytosolic ERK5 in neuroblastoma pediatric cancer
9:25 - 09:50	Azuzena Esparís-Ogando (IBSAL, Salamanca, Spain) The tumorigenic potential of the MEK5/ERK5 route
09:50 - 10:15	Martin Villalba (INSERM, Montpellier, France) Tumor cell metabolism and tumor immune escape: the role of ERK5
10:15 - 11:30	Coffe break
11:30 - 12:20	Session 6 - Moderator: Elisabetta Rovida
11:30 - 11:55	Marc Schmidt University (Hospital Würzburg, Germany) The MEK5/ERK5 cascade as therapy-resistance pathway in NRAS-mutant melanoma
11:55 - 12:20	Jane E Cavanaugh (Duquesne University, Pittsburgh, USA) Involvement of the ERK5 pathway in neurodegeneration and breast cancer
12:20 - 13:00	VHIR International Project Management Office Funding opportunities
13:00 - 14:30	Lunch
14.30 - 16.00	Thematic round tables
14:30 - 15:00	Simon Cook, Atanasio Pandiella, Katherine Finegan Development of ERK5 inhibitors for the clinic
15:00 - 15:30	Cathy Tournier, Martin Villaba, Emanuele Giurisato ERK5 in immunity and inflammation
15:30 - 16:00	Azucena Espatis-Ogando, Elisabetta Rovida, Jose Lizcano Identification of biomarkers of ERK5 signaling
16:00 - 17.00	Greetings & concluding remarks

